This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bellicum Pharmaceuticals, Inc.
Drug Names(s): CaspaCIDe enabled T cells, CaspaCIDe System and Rimiducid, BPX501
Description: CaspaCIDe is directed toward improving the safety and efficacy of cell therapies by providing physicians with greater control over the function and fate of the implanted cells.
The CaspaCIDe technology involves pre-transplant transfection of the donor cells with a chemically inducible suicide (apoptosis) gene and a gene for a cell surface marker that permits sorting, isolation and post-implant monitoring of successfully transfected cells. The chemically-induced apoptosis is accomplished via a modified version of the caspase-9 protein that undergoes dimerization (and thus, activation) under the influence of a small molecule dimerization enhancer, AP1903.
Deal Structure: In October 2008, Bellicum entered into a non-exclusive, royalty-bearing licensing agreement with ARIAD Pharmaceuticals for ARIAD's ARGENT cell-signaling regulation technology, on which CaspaCIDe is based. ARIAD will have an equity stake in Bellicum and will receive additional payments. Bellicum also may be granted exclusive licenses in certain product applications based on its achievement of development, regulatory and commercial milestones.
Partners: ARIAD Pharmaceuticals, Inc.
Additional information available to subscribers only: